Engineering High-Performance Microbial Chassis for Robust Industrial Biomanufacturing. Pseudomonas putida, particularly the KT2440 strain, is recognized as a premier synthetic biology chassis due to its extraordinary metabolic versatility and natural endowment to withstand industrial-scale stress. CD Biosynsis provides professional Pseudomonas putida Strain Development and Screening Services, integrating advanced CRISPR genome editing, evolutionary engineering, and systematic multi-omics analysis. We empower clients in the chemical, pharmaceutical, and food industries to develop customized strains capable of converting low-cost feedstocks into high-value chemicals with unprecedented stability and safety.
Get a Technical QuoteOur platform offers an end-to-end solution for strain development, from initial safety assessments and genomic streamlining to high-throughput phenotypic screening under industrial-scale conditions.
| Service Tier | Technical Strategy | Primary Application | Standard Deliverables |
|---|---|---|---|
| Industrial Chassis Development | CRISPR/Cas editing & Synthetic Biology | Bioplastics, solvents, & drug precursors | Optimized "Clean" chassis + WGS report |
| Stress Resistance Screening | Metabolomics & Metabolic Flux Analysis | Large-scale fermentation (High pH/Solvent) | Stress-tolerant strains + Adaptive models |
| Directed Evolution (ALE) | Systems Evolution Platform | Waste-to-value (Glycerol/Lignocellulose) | Evolution-optimized strains + Flux maps |
| Safety & QPS Assessment | Genomic virulence factor screening | Food additives & Feed enzymes | EFSA-compliant safety dossiers |
1. Chassis Selection & Safety Profiling
2. Rational Design & Engineering
3. Adaptive Evolution (ALE)
4. Multi-Omics Screening
Screening the genome for safety markers and regulatory compliance (QPS standards) for the target industry.
Formal project proposal and Mutual NDA signing.
Utilizing CRISPR/Cas systems to insert synthetic pathways and remove metabolic "drag" genes.
Predictive metabolic modeling to optimize carbon flux distribution.
Subjecting strains to directed evolution under specific industrial pressures (e.g., toxic substrates or extreme pH).
Restoring host fitness while maintaining high production titers.
High-throughput metabolomics and Metabolic Flux Analysis (MFA) to evaluate carbon distribution.
Final pilot-scale validation in bioreactors to ensure performance translates to industrial stress.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research and safety guidelines.
Large-scale fermentation subjects microbes to pH fluctuations and oxidative stress. Technical benchmarks confirmed that P. putida KT2440 is naturally endowed with high solvent tolerance. By establishing metabolic flux models, researchers identified glutathione metabolism as critical for redox balance, reducing production fluctuations during scale-up.
(Reference: P. putida Industrial Stress Resilience, 2020)
To accelerate production of bio-plastics and pharmaceutical precursors, researchers utilize a "Synthetic Biology Chassis" strategy. This involves using CRISPR/Cas tools to optimize metabolic flow. Systematic modeling of metabolic loads allows for the rapid construction and screening of high-titer strains for chemical enterprises.
(Reference: Industrial Biotechnology of P. putida, 2020)
Turning pollutants into profit requires strains with flexible substrates. Utilizing a "Systems Evolution Platform," P. putida has been evolved to grow on low-cost waste like glycerol effluents and wood hydrolysates. These strains exhibit optimized carbon allocation, providing a sustainable route for the circular bioeconomy.
(Reference: P. putida Industrial Biotechnology, 2023)
Safety is the primary barrier in the food industry. Genomic comparisons and virulence factor screening confirmed P. putida as a non-pathogenic agent suitable for additive production. By ensuring the lack of critical virulence factors like Exotoxin A, strains meet EFSA safety recommendations (QPS) for enzymes and bioactive peptides.
(Reference: EFSA QPS Update 19, 2024)
Ready to engineer your high-performance industrial chassis?
Contact Us1. Is P. putida safe for use in food-grade enzyme production?
Yes. According to the 2024 EFSA QPS updates, P. putida is recognized as a safe agent. We provide genomic screening to ensure your strain is free of virulence factors and safe for food-related applications.
2. How does P. putida handle toxic substrates like aromatic compounds?
Unlike many microbes, P. putida has naturally evolved to degrade and tolerate aromatic solvents. We further enhance this through directed evolution to ensure productivity in the presence of inhibitory precursors.
3. What is the benefit of "Genomic Streamlining"?
By removing non-essential genes and virulence factors, we reduce the metabolic burden. This redirects more cellular energy and carbon toward your target chemical, increasing overall yield.
4. How do you ensure the stability of traits during large-scale fermentation?
We conduct long-term stability testing and utilize genomic integration rather than plasmid-based expression to ensure pathways are permanently maintained without expensive antibiotics.
5. What is the typical timeline for a strain development project?
A standard project—from initial design and engineering to evolution and screening—typically takes 12 to 20 weeks, depending on pathway complexity and tolerance requirements.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.